Effect of Systemic Infliximab Therapy in Patients with Sjögren's Syndrome.

Turk J Ophthalmol 2015 Aug 5;45(4):138-141. Epub 2015 Aug 5.

Akdeniz University Faculty of Medicine, Department of Ophthalmology, Antalya, Turkey.

Objectives: To investigate the effect of systemic infliximab therapy on tear function tests and the ocular surface in patients with Sjögren's syndrome secondary to various autoimmune diseases.

Ma­te­ri­als And Met­hods: This prospective study included 22 eyes of 22 patients with Sjögren's syndrome who began treatment with systemic infliximab. Tear film break-up time (TBUT), anesthetized Schirmer's 1 test, fluorescein staining test, and Ocular Surface Disease Index (OSDI) scores were recorded before treatment and in the 3rd and 6th months of treatment.

Re­sults: In the 3rd month of infliximab therapy, no significant changes were observed in Schirmer's values, TBUT, fluorescein staining, or OSDI scores (p=0.260, p=0.357, p=0.190 and p=0.07, respectively). In the 6th month of infliximab therapy, no significant changes were observed in TBUT, fluorescein staining, Schirmer's value or OSDI scores (p=0.510, p=0.320, p=0.220 and p=0.344, respectively).

Conclusion: Infliximab therapy, which is commonly used in systemic autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis, did not show a positive effect on ocular surface and tear function tests.

Download full-text PDF

Source
http://dx.doi.org/10.4274/tjo.48379DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082270PMC
August 2015
7 Reads

Publication Analysis

Top Keywords

infliximab therapy
20
fluorescein staining
12
patients sjögren's
12
sjögren's syndrome
12
osdi scores
12
systemic infliximab
12
ocular surface
12
changes observed
8
tear function
8
tbut fluorescein
8
therapy changes
8
month infliximab
8
function tests
8
infliximab
5
therapy
5
p=0190 p=007
4
anesthetized schirmer's
4
schirmer's test
4
p=0357 p=0190
4
p=0260 p=0357
4

Similar Publications